Rye, NH, United States of America

Mark R Brann

USPTO Granted Patents = 25 


 

Average Co-Inventor Count = 3.2

ph-index = 18

Forward Citations = 682(Granted Patents)


Location History:

  • San Diego, CA (US) (2002 - 2009)
  • Del Mar, CA (US) (2008 - 2011)
  • Rye, NH (US) (2009 - 2020)

Company Filing History:


Years Active: 2002-2020

Loading Chart...
Loading Chart...
Loading Chart...
25 patents (USPTO):Explore Patents

Title: The Innovative Path of Mark R Brann in Neuropharmacology

Introduction

Mark R Brann, based in Rye, NH, is a prominent figure in the field of neuropharmacology, holding an impressive portfolio of 25 patents. His groundbreaking work focuses on the development of novel therapeutics aimed at addressing significant neurological challenges, particularly in relation to psychosis and neurodegenerative diseases.

Latest Patents

Among Brann's latest innovations is his patent for selective serotonin 2A/2C receptor inverse agonists. This compound, referred to as formula (I), has demonstrated considerable efficacy in behavioral pharmacological studies, particularly in models of psychosis and dyskinesias. The data reveal that this compound can effectively reverse MK-801 induced locomotor behaviors, thereby suggesting its potential as an efficacious anti-psychotic. Additionally, it has shown activity in an MPTP primate model of dyskinesias, indicating its promise as an anti-dyskinesia agent. The hypothesis driving this research proposes that 5HT2A/2C receptor inverse agonism can provide antipsychotic and anti-dyskinetic efficacy for human patients, highlighting potential applications for Parkinson's Disease and related neurodegenerative conditions.

Career Highlights

Throughout his career, Mark Brann has made substantial contributions to the field while working with notable firms including Acadia Pharmaceuticals Inc. His extensive work in the industry has facilitated advancements in the development of unique compounds that target critical neurological pathways.

Collaborations

Brann has had the opportunity to collaborate with esteemed professionals in the field, such as David M Weiner and Robert E Davis. These collaborations have likely accelerated the progress of his research and patent development, enriching the knowledge base in neuropharmacology.

Conclusion

In conclusion, Mark R Brann stands out as an influential inventor in the realm of neuropharmacology. His innovative approaches and the substantial impact of his patents reflect a commitment to improving therapeutic options for patients suffering from neurodegenerative diseases. As his work continues to evolve, it holds great promise for advancing treatments in psychosis and related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…